GIP and GLP-1 receptor agonist studied in glucose and weight management.
Tirzepatide is a synthetic peptide that acts on two incretin receptors, GIP and GLP-1. Research examines its relationship with insulin secretion, appetite, and gastric emptying.
Research examines its relationship with glucose control, appetite, and weight management in specific clinical settings.
Results from trials of specific medicines do not establish the efficacy, safety, or authorization of a different commercial vial.
Before interpreting a page, confirm the exact compound, formulation, and presentation. For personal decisions, consult a healthcare professional; this information does not establish a dose or indication for you.
Tirzepatide acts on GIP and GLP-1; semaglutide acts on GLP-1. They are not the same compound.
No. They describe an amount of substance, not the amount suitable for a person.
Check compound identity, formulation, route, studied population, and the original study. Seek qualified advice for personal decisions.
Online customer service and shipping throughout Costa Rica.
tribiopeptidoscr@gmail.com